Novo Nordisk A S (NVO)
NYSE · Price as of · Nasdaq Real Time Price
- Analysts12
- Implied upside+22.9%
- Target range$39.25 to $62.12
How Congress has done in NVO
Every purchase of NVO disclosed by a member of Congress in the last 5 years, scored over the 12 months after the trade date against SPY over the same window.
| Measure | NVO | SPY |
|---|---|---|
| Median 12-month return after purchase | -15.7% | +20.7% |
| Median difference vs SPY | -34.4% | — |
| Purchases that beat SPY | 0 of 8 (0%) | — |
| Members who bought | 3 | — |
Most frequent buyers: Scott Franklin (4), Lisa McClain (2), Marjorie Taylor Greene (2).
These are not returns anyone actually earned. Disclosures report a dollar bracket and no share count, so every purchase is counted once and weighted equally, and sales are not matched back to the buys that opened them. 3 of the 8 purchases are disclosed as a spouse's or dependent's rather than the member's own. Purchases from the last 12 months are excluded because their window has not closed yet.
Congress trades in NVO
| Date | Member | Action | Amount | |
|---|---|---|---|---|
| 2026-09-10 | Kevin Hern OK | Sale | $1,001 - $15,000 | |
| 2026-08-31 | Kevin Hern OK | Sale (Partial) | $1,001 - $15,000 | |
| 2026-08-31 | Kevin Hern OK | Sale | $1,001 - $15,000 | |
| 2026-08-26 | Scott Franklin FL | Purchase | $1,001 - $15,000 |
SEC filings
| Form | Filed | Description |
|---|---|---|
| 6-K | September 28, 2026 | FORM 6-K |
| 6-K | September 21, 2026 | FORM 6-K |
| 6-K | September 17, 2026 | FORM 6-K |
| 6-K | September 15, 2026 | FORM 6-K |
| 6-K | September 9, 2026 | FORM 6-K |
| 6-K | August 31, 2026 | FORM 6-K |
| 6-K | August 24, 2026 | FORM 6-K |
| 6-K | August 18, 2026 | FORM 6-K |
Articles that mention Novo Nordisk A S without it being the main subject.
Frequently asked questions
When does NVO report earnings?
Novo Nordisk A S (NVO) is scheduled to report quarterly results on November 4, 2026, before the open. Its results are reported in DKK, so we show the date only rather than presenting a consensus in another currency as dollars. It has beaten the consensus EPS estimate in 3 of the last four quarters.
What do analysts expect for NVO?
12 analysts cover Novo Nordisk A S (NVO). The consensus rating is Hold. The average price target is $45.88, in a range of $39.25 to $62.12.
Are insiders buying or selling NVO?
We have no qualifying Form 4 insider purchases or sales on record for Novo Nordisk A S (NVO). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Has Congress made money trading NVO?
3 members of Congress have disclosed buying NVO in the last 5 years, 8 purchases in total. Measured over the 12 months after each trade date, the median purchase returned -15.7% against +20.7% for SPY over the same windows, and 0 of the 8 (0%) beat the index. These are not returns anyone actually earned: congressional disclosures report a dollar bracket and no share count, so each purchase is counted once and weighted equally, and later sales are not matched back to the buys that opened them.
Where can I see NVO SEC filings?
Recent filings are listed on this page, newest first. The latest is a 6-K filed September 28, 2026.